Pfizer and its partner BioNTech say their coronavirus vaccine is 90 percent effective in Phase III trials. How excited should we be about the news and what questions go unanswered?
health
November 9, 2020
By
A health worker in Turkey holds a syringe in hand during the Phase III trial of the coronavirus vaccine candidate developed by Pfizer and BioNTech
Photo by Dogukan Keskinkilic / Anadolu Agency via Getty Images
US drug maker Pfizer and its German partner BioNTech today published some positive-looking clinical trial results with their experimental Covid-19 vaccine BNT162b2.
The headline is “90 percent effective”. But that may not be as good news as it first appears.
What did Pfizer and BioNTech find?
The results come from a phase III clinical study, the final phase of testing whether a …
You may also like
-
COVID Vaccine Tracker
-
New Bariatric Portion Plate Helps Bariatric Patients Reach Their Goals
-
2021 preview: how soon will a Covid-19 vaccine normalize life?
-
Official British statisticians had concerns about the trend in the Covid-19 poll
-
NASA’s probe on Mars may feel the ground shake when rovers land in 2021